Ascendis Pharma Oncology Division A/S
2 clinical trials · Sponsor
◉ Watch Ascendis Pharma Oncology Division A/S
| Record | Firm | Date |
|---|---|---|
| A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (NCT05081609) | Ascendis Pharma Oncology Division A/S | 2022-01-11 |
| A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors (NCT04799054) | Ascendis Pharma Oncology Division A/S | 2021-03-18 |
Track Ascendis Pharma Oncology Division A/S automatically
Every clearance here is in the API, with alerts when new ones post.